Trinity Biotech plc

NasdaqGS:TRIB Lagerbericht

Marktkapitalisierung: US$19.7m

Trinity Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Trinity Biotech wird ein Gewinn- und Umsatzwachstum von 66.1% bzw. 12.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 72.2% pro Jahr wachsen soll.

Wichtige Informationen

66.1%

Wachstumsrate der Gewinne

72.2%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum16.6%
Wachstumsrate der Einnahmen12.9%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert29 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18
Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Sep 12
A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Aug 08
Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Jun 09
Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

Apr 23
Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23
This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01
Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01
At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)

Jun 14
Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 23
Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?

Feb 25
Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?

Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability

Feb 02
Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability

A Treatise On Trinity Biotech

Jan 13

Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?

Jan 05
Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?

What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?

Dec 10
What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?

Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt

Nov 19
Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt

Trinity Biotech EPS beats by $0.22, beats on revenue

Nov 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:TRIB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202571-9-5-11
12/31/202463-19-12-81
3/31/202457-34-15-12N/A
12/31/202357-37-14-12N/A
9/30/202371-39-13-10N/A
6/30/202372-42-8-5N/A
3/31/202374-34-7-2N/A
12/31/202263-44-7-1N/A
9/30/202276-32-62N/A
6/30/202279-22-53N/A
3/31/202286-13-26N/A
12/31/202181-2513N/A
9/30/2021106-81120N/A
6/30/2021116-21827N/A
3/31/2021106-21929N/A
12/31/2020102-61424N/A
9/30/202091-20-17N/A
6/30/202083-27-65N/A
3/31/202090-31-210N/A
12/31/201990-29-65N/A
9/30/201994-30-411N/A
6/30/201993-29-79N/A
3/31/201995-23-79N/A
12/31/201897-23-107N/A
9/30/201897-39-107N/A
6/30/201899-40-88N/A
3/31/201899-40-610N/A
12/31/201799-39N/A9N/A
9/30/201798-36N/A8N/A
6/30/201799-37N/A10N/A
3/31/2017100-36N/A8N/A
12/31/2016100-39N/A10N/A
9/30/20161013N/A17N/A
6/30/201610116N/A14N/A
3/31/20169816N/A13N/A
12/31/201510022N/A13N/A
9/30/201510123N/A15N/A
6/30/201510315N/A17N/A
3/31/201510517N/A16N/A
12/31/201410515N/A16N/A
9/30/201410318N/A8N/A
6/30/201410010N/A6N/A
3/31/20149510N/A8N/A
12/31/20139110N/A9N/A
9/30/2013869N/A15N/A
6/30/20138317N/A17N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TRIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TRIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TRIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TRIBDie Einnahmen des Unternehmens (12.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: TRIBDie Einnahmen des Unternehmens (12.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TRIB in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y